Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.37 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 2/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1124266 | 0.83 | CNR1 (0.38) | KIF11SIGMAR1 | |
| SCHEMBL9637154 | 0.78 | FOLH1 (0.42) | IDO1 | |
| SCHEMBL16266794 | 0.78 | — | — | |
| SCHEMBL7850102 | 0.78 | TP53 (0.42) | TP53MGLLCYP1A2CYP2A6BCL2 | |
| Bromide SCHEMBL11151689 | 0.77 | TP53 (0.41) | TP53MGLLCYP1A2CYP2A6BCL2 | |
| SCHEMBL166894 | 0.75 | TP53 (0.61) | TP53MGLLCYP1A2CYP2A6BCL2 | |
| Ammonia Solution, Strong SCHEMBL28805948 | 0.73 | TP53 (0.58) | TP53MGLLCYP1A2CYP2A6BCL2 | |
| Benzene SCHEMBL9785236 | 0.73 | TP53 (0.67) | TP53MGLLCYP1A2CYP2A6BCL2 | |
| SCHEMBL28256639 | 0.73 | TP53 (0.58) | TP53MGLLCYP1A2CYP2A6BCL2 | |
| Bromide SCHEMBL8523958 | 0.72 | XDH (0.40) | TP53CYP1A2SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110372468-B | Hydrogenated endless [8] arene compound and preparation method thereof | 清华大学 | 2020-11-10 | — | — | CN | claimed |
| CN-110372469-B | Hydrogenated cyclo [12] arene compound and preparation method thereof | 清华大学 | 2020-09-08 | — | — | CN | claimed |
| WO-2021012478-A1 | HYDROGENATION ANNULE [12] AROMATIC COMPOUND AND PREPARATION METHOD THEREFOR | 清华大学 | 2021-01-28 | — | — | WO | disclosed |
| WO-2021012479-A1 | HYDROGENATED CYCLIC [8] AROMATIC HYDROCARBON COMPOUND AND PREPARATION METHOD THEREFOR | 清华大学 | 2021-01-28 | — | — | WO | disclosed |
| CN-110372468-B | Hydrogenated endless [8] arene compound and preparation method thereof | 清华大学 | 2020-11-10 | — | — | CN | disclosed |
| CN-110372469-B | Hydrogenated cyclo [12] arene compound and preparation method thereof | 清华大学 | 2020-09-08 | — | — | CN | disclosed |
| EP-3292128-A1 | 5'-SUBSTITUTED NUCLEOSIDE ANALOGS | Eli Lilly and Company (US) | 2018-03-14 | — | — | EP | disclosed |
| US-9840532-B2 | 5′-substituted nucleoside compounds | ELI LILLY AND COMPANY (US) | 2017-12-12 | — | — | US | disclosed |
| WO-2017158147-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017158151-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-09-21 | — | — | WO | disclosed |
| US-20160326208-A1 | 5'-SUBSTITUTED NUCLEOSIDE COMPOUNDS | ELI LILLY AND COMPANY | 2016-11-10 | — | — | US | disclosed |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | VITAE PHARMACEUTICAL, INC (US) | 2009-01-15 | — | — | US | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| WO-2008076048-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| EP-1807078-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1692111-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | Wyeth, A Corporation of the State of Delaware (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2006042150-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005058834-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | WYETH (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
| US-4088644-A | N-Acyl-3-azetidinone | SCHERING-CORPORATION (US) | 1978-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214641-A1 | Chemical compounds 572 | ABCG2, ABCB1, CYP11B2 | TP53 2729/4885MGLL 2475/4885CYP1A2 20/4885 |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | DNPEP, PEPD, ACE | TP53 1848/4885MGLL 3120/4885CYP1A2 2137/4885 |
| US-20160326208-A1 | 5'-SUBSTITUTED NUCLEOSIDE COMPOUNDS | NT5C3B, MCL1, NSUN2 | TP53 52/4885MGLL 2341/4885CYP1A2 4414/4885 |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | NR1H2, NR1H3, SREBF1 | TP53 4850/4885MGLL 396/4885CYP1A2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.